XML 33 R24.htm IDEA: XBRL DOCUMENT v3.22.2
Consolidated Entities (Tables)
6 Months Ended
Jun. 30, 2022
Theravance Respiratory Company, LLC  
Consolidated Entities  
Schedule of Balance Sheets and Income Statements of VIE

The summarized financial information for TRC is presented as follows:

Balance sheets

 

 

 

June 30,

 

 

December 31,

 

(In thousands)

 

2022

 

 

2021

 

Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

89,806

 

 

$

50,713

 

Receivables from collaborative arrangements

 

 

42,720

 

 

 

42,492

 

Prepaid expenses and other current assets

 

 

85

 

 

 

71

 

Equity and long-term investments

 

 

42,536

 

 

 

37,695

 

Total assets

 

$

175,147

 

 

$

130,971

 

 

 

 

 

 

 

 

Liabilities and LLC Members’ Equity

 

 

 

 

 

 

Current liabilities

 

$

493

 

 

$

252

 

LLC members’ equity

 

 

174,654

 

 

 

130,719

 

Total liabilities and LLC members’ equity

 

$

175,147

 

 

$

130,971

 

 

Income statements

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

(In thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Royalty revenue from a related party

 

$

42,720

 

 

$

26,386

 

 

$

72,029

 

 

$

48,470

 

Operating expenses

 

 

139

 

 

 

336

 

 

 

337

 

 

 

3,617

 

Income from operations

 

 

42,581

 

 

 

26,050

 

 

 

71,692

 

 

 

44,853

 

Other income, net

 

 

10

 

 

 

 

 

 

10

 

 

 

 

Income tax expense, net

 

 

 

 

 

 

 

 

1

 

 

 

 

Changes in fair values of equity and long-term
   investments

 

 

(9,313

)

 

 

(254

)

 

 

(8,884

)

 

 

(737

)

Net income

 

$

33,278

 

 

$

25,796

 

 

$

62,819

 

 

$

44,116

 

Entasis Therapeutics Holdings Inc  
Consolidated Entities  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the preliminary allocation of the fair values assigned to the assets acquired and liabilities assumed as of the date of the consolidation:

 

(In thousands)

 

February 17, 2022

 

Cash and cash equivalents

 

$

23,070

 

Prepaid expenses

 

 

5,554

 

Other current assets

 

 

1,959

 

Property and equipment, net

 

 

185

 

Right-of-use assets

 

 

527

 

Goodwill

 

 

5,544

 

Intangible assets

 

 

105,000

 

Other assets

 

 

302

 

Total assets acquired

 

$

142,141

 

 

 

 

 

Accounts payable

 

$

1,583

 

Accrued personnel-related expenses

 

 

1,057

 

Other current liabilities

 

 

5,096

 

Total liabilities assumed

 

$

7,736

 

 

 

 

 

Total assets acquired, net

 

$

134,405

 

Schedule of Balance Sheet Information The following table provides the assets and liabilities of Entasis:

 

(In thousands)

 

June 30, 2022

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

 

$

22,408

 

Prepaid expenses

 

 

3,177

 

Other current assets

 

 

1,035

 

Total current assets

 

 

26,620

 

Property and equipment, net

 

 

171

 

Right-of-use assets

 

 

3,503

 

Goodwill

 

 

5,544

 

Intangible assets

 

 

105,000

 

Other assets

 

 

1,147

 

Total assets

 

$

141,985

 

 

 

 

 

Liabilities

 

 

 

Current liabilities:

 

 

 

Accounts payable

 

$

4,025

 

Accrued personnel-related expenses

 

 

3,385

 

Other accrued liabilities

 

 

8,195

 

Total current liabilities

 

 

15,605

 

Lease liabilities, long-term

 

 

3,091

 

Total liabilities

 

$

18,696

 

Pro Forma Information

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

(In thousands)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Revenue

 

$

108,220

 

 

$

100,806

 

 

$

198,279

 

 

$

186,324

 

Net income

 

$

17,221

 

 

$

34,140

 

 

$

55,248

 

 

$

144,490

 

Net income attributable to Innoviva stockholders

 

$

(3,306

)

 

$

17,063

 

 

$

15,727

 

 

$

116,130